Thesite is secure.
The ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Objectives: This study aimed to validate the two total scores (TS-I and TS-II) of the Consortium to Establish a Registry for Alzheimer Disease neuropsychological battery (CERAD-NP) for a large elderly population including mild cognitive impairment (MCI) and dementia patients with various etiologic backgrounds. The authors also investigated whether the addition of frontal-executive function score can improve the discrimination accuracy of the total scores for dementia and MCI.
Results: Both TS-I and TS-II were highly correlated with other global cognitive and functional scales. Both total scores showed, though modest, superior NC versus MCI discrimination ability to Mini-Mental State Examination (MMSE). Their discrimination ability for NC versus dementia was excellent and significantly better, especially in discriminating very mild dementia, than MMSE. The addition of frontal-executive test score to TS-I or TS-II did not make a significant improvement in dementia or MCI discrimination ability. Both of them also showed higher test-retest and interrater reliability than MMSE or any individual neuropsychological tests in the CERAD-NP.
Conclusion: These results strongly support the validity and usefulness of CERAD total scores for early detection and progression monitoring of MCI and dementia in clinical and research settings.
The Seoul Neuropsychological Screening Battery (SNSB) is known as a representative comprehensive neuropsychological evaluation tool in Korea since its first standardization in 2003. It was the main neuropsychological evaluation tool in the Clinical Research Center for Dementia of South Korea, a large-scale multi-center cohort study in Korea that was started in 2005. Since then, it has been widely used by dementia clinicians, and further solidified its status as a representative dementia evaluation tool in Korea. Many research results related to the SNSB have been used as a basis for the diagnosis and evaluation of patients in various clinical settings, especially, in many areas of cognitive assessment, including dementia evaluation. The SNSB version that was updated in 2012 provides psychometrically improved norms and indicators through a model-based standardization procedure based on a theoretical probability distribution in the norm's development. By providing a score for each cognitive domain, it is easier to compare cognitive abilities between domains and to identify changes in cognitive domain functions over time. Through the development of the SNSB-Core, a short form composed of core tests, which also give a composite score was provided. The SNSB is a useful test battery that provides key information on the evaluation of early cognitive decline, analysis of cognitive decline patterns, judging the severity of dementia, and differential diagnosis of dementia. This review will provide a broad understanding of the SNSB by describing the test composition, contents of individual subtests, characteristics of standardization, analysis of the changed standard score, and related studies.
During the medical workup, the health care provider will review the person's medical history, including psychiatric history and history of cognitive and behavioral changes. He or she will want to know about any current and past medical problems and concerns, as well as any medications the person is taking. The doctor will also ask about key medical conditions affecting other family members, including whether they may have had Alzheimer's disease or other dementias.
During a neurological exam, the physician will closely evaluate the person for problems that may signal brain disorders other than Alzheimer's. The doctor will look for signs of stroke, Parkinson's disease, brain tumors, buildup of fluid in the brain, and other conditions that may impair memory or thinking.
The physician will test:
Home screening tests for dementia A number of dementia screening tests have been marketed directly to consumers. None of these tests have been scientifically proven to be accurate. Furthermore, the tests can have false-positive results, meaning that individuals can have results saying they have dementia when in fact they do not. This is extremely unlikely to happen if the individual visits a physician to seek care and potential diagnosis. For these and other reasons, the Alzheimer's Association believes that home screening tests cannot and should not be used as a substitute for a thorough examination by a skilled doctor. The whole process of assessment and diagnosis should be carried out within the context of an ongoing relationship with a responsible and qualified health care professional.
Cognitive, functional and behavioral tests evaluate memory, thinking and simple problem-solving abilities, and may quickly assess changes in behaviors and symptoms. Some tests are brief, while others can be more time intensive and complex. More comprehensive cognitive, functional and behavioral tests are often given by a neuropsychologist to evaluate executive function, judgment, attention and language.
Such tests may give an overall sense of whether a person is experiencing cognitive symptoms that affect activities of daily living and function and is aware of these symptoms; knows the date, time and where he or she is; and can remember a short list of words, follow instructions and perform simple calculations.
Examples of cognitive, functional and behavioral tests include:
Neuropsychologists provide detailed assessments of cognitive and emotional functioning that often cannot be obtained through other diagnostic means. They use standardized assessment tools and integrate the findings with other data to determine whether cognitive decline has occurred, to differentiate neurologic from psychiatric conditions, to identify neurocognitive etiologies, and to determine the relationship between neurologic factors and difficulties in daily functioning. Family physicians should consider referring patients when there are questions about diagnostic decision making or planning of individualized management strategies for patients with mild cognitive impairment, dementia, traumatic brain injury, and other clinical conditions that affect cognitive functioning. Neuropsychological testing can differentiate Alzheimer dementia from nondementia with nearly 90% accuracy. The addition of neuropsychological testing to injury severity variables (e.g., posttraumatic amnesia) increases predicted accuracy in functional outcomes. A neuropsychological evaluation can be helpful in addressing concerns about functional capacities (e.g., ability to drive or live independently) and in determining a patient's capacity to make decisions about health care or finances. Most patients who underwent neuropsychological evaluation and their significant others reported that they found the evaluation helpful in understanding and coping with cognitive problems.
Family physicians are often the first health care professionals to evaluate patients with memory loss and cognitive dysfunction. Although many patients can be readily diagnosed and treated, some present significant challenges. A neuropsychological consultation can help characterize cognitive deficits, clarify diagnoses, and develop optimal management plans for patients with cognitive issues.1 Common goals of neuropsychological evaluations are provided in Table 1.2
Clinical neuropsychologists are doctoral-level psychologists who have fellowship training in assessment and intervention principles that are based on the scientific study of human behavior as it relates to normal and abnormal brain functioning.1 Neuropsychologists use validated puzzle-based materials, oral questions, and written tests to objectively assess multiple cognitive and emotional functions (Table 2). The tests are typically standardized using large normative samples of healthy age-matched individuals, allowing the examiner to determine the degree to which performance deviates from expected ranges. The results of neuropsychological testing are integrated with other sources of information to provide a comprehensive assessment of a person's cognitive, behavioral, and emotional functioning as a basis for clinical decisions (Table 3).2
Neuropsychological tests are different in purpose and scope from cognitive screening tests such as the Mini-Mental State Examination3 (Table 4). Screening tests usually take five to 10 minutes to complete and are designed to screen for general cognitive impairment that may warrant a more comprehensive workup. Although screening tests can indicate problems in general cognitive functioning, they have poor ability to assess for deficits in specific cognitive domains. This has been highlighted by research showing that screening test items weakly correlate with scores in the same cognitive domains on neuropsychological testing (correlations range from 0.04 to 0.46).4 Neuropsychological testing typically requires several hours to complete because it comprehensively examines multiple cognitive domains to provide a detailed assessment of the nature and severity of cognitive impairments. This information can contribute significantly when determining primary and secondary diagnoses and planning an individualized rehabilitation/treatment plan.3
Neuropsychological evaluations are often complementary to neuroimaging and electrophysiologic procedures.5 Computed tomography and magnetic resonance imaging evaluate structural integrity within the central nervous system to identify atrophy and lesions. Electroencephalography detects electrical activity of the brain, which is commonly used to assess for epileptic activity. Positron emission tomography identifies cerebral glucose metabolism to determine whether brain activity is reduced in specific regions. However, these procedures have limited diagnostic sensitivity for some neurologic conditions and cannot assess the functional output of the brain. Neuropsychological testing provides an objective assessment of the cognitive, behavioral, and emotional manifestations from cerebral injury or disease.
3a8082e126